Compare Stocks → Uncover this 2024 Hidden Gem (From Tips4Traders) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:BCLINASDAQ:FENCNASDAQ:GNFTNASDAQ:JNCENASDAQ:LJPC Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCLIBrainstorm Cell Therapeutics$0.54+1.9%$0.46$0.13▼$3.37$36.96M0.281.02 million shs528,793 shsFENCFennec Pharmaceuticals$9.70-5.5%$10.10$6.30▼$11.92$262.87M0.38110,123 shs249,137 shsGNFTGenfit$3.46-4.7%$3.63$2.89▼$4.75$172.41M1.0815,652 shs3,416 shsJNCEJounce Therapeutics$1.88-2.6%$1.89$0.58▼$5.87$98.94M0.752.46 million shs11.60 million shsLJPCLa Jolla Pharmaceutical$5.73$3.07▼$6.24$155.11M2.39158,476 shs66,708 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCLIBrainstorm Cell Therapeutics-3.94%-9.51%+58.34%+61.49%-79.80%FENCFennec Pharmaceuticals-0.68%-5.79%+3.22%-0.39%+25.12%GNFTGenfit+3.42%-2.68%+3.13%+7.40%-6.44%JNCEJounce Therapeutics0.00%0.00%0.00%0.00%-2.08%LJPCLa Jolla Pharmaceutical0.00%0.00%0.00%0.00%0.00%Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (Ad)Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guideMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCLIBrainstorm Cell Therapeutics1.2062 of 5 stars0.03.00.04.73.60.00.6FENCFennec Pharmaceuticals1.8592 of 5 stars3.50.00.00.01.02.51.9GNFTGenfit0.8024 of 5 stars3.53.00.00.00.60.00.0JNCEJounce TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ALJPCLa Jolla PharmaceuticalN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCLIBrainstorm Cell Therapeutics2.00HoldN/AN/AFENCFennec Pharmaceuticals3.00Buy$17.3378.69% UpsideGNFTGenfit3.00Buy$11.00217.92% UpsideJNCEJounce TherapeuticsN/AN/AN/AN/ALJPCLa Jolla PharmaceuticalN/AN/AN/AN/ACurrent Analyst RatingsLatest BCLI, JNCE, FENC, LJPC, and GNFT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/5/2024GNFTGenfitHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.004/4/2024FENCFennec PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$17.00 ➝ $18.003/18/2024FENCFennec PharmaceuticalsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$17.00 ➝ $18.003/18/2024FENCFennec PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$16.00(Data available from 4/17/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCLIBrainstorm Cell TherapeuticsN/AN/AN/AN/A($0.08) per shareN/AFENCFennec Pharmaceuticals$21.25M12.37N/AN/A($0.43) per share-22.56GNFTGenfit$41.31M4.17N/AN/A$1.48 per share2.34JNCEJounce Therapeutics$82M1.21N/AN/A$3.54 per share0.53LJPCLa Jolla Pharmaceutical$75.72M0.00N/A7.95($2.94) per share0.00Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCLIBrainstorm Cell Therapeutics-$17.19M-$0.41N/AN/AN/AN/AN/A-376.40%5/20/2024 (Estimated)FENCFennec Pharmaceuticals-$16.05M-$0.61N/A13.86N/A-75.50%N/A-73.64%5/9/2024 (Estimated)GNFTGenfit-$31.27MN/A0.00N/AN/AN/AN/AN/A7/4/2024 (Estimated)JNCEJounce Therapeutics-$50.92M-$2.56N/AN/AN/AN/A-30.90%-26.31%N/ALJPCLa Jolla Pharmaceutical$19.66M$0.1251.840.00N/A8.54%-5.46%4.00%N/ALatest BCLI, JNCE, FENC, LJPC, and GNFT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/21/2024Q4 2023FENCFennec Pharmaceuticals$0.02-$0.10-$0.12-$0.10$9.47 million$9.74 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCLIBrainstorm Cell TherapeuticsN/AN/AN/AN/AN/AFENCFennec PharmaceuticalsN/AN/AN/AN/AN/AGNFTGenfitN/AN/AN/AN/AN/AJNCEJounce TherapeuticsN/AN/AN/AN/AN/ALJPCLa Jolla PharmaceuticalN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCLIBrainstorm Cell TherapeuticsN/A0.240.24FENCFennec PharmaceuticalsN/A3.563.27GNFTGenfit0.922.942.94JNCEJounce TherapeuticsN/A8.378.37LJPCLa Jolla PharmaceuticalN/A4.023.52OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCLIBrainstorm Cell Therapeutics14.33%FENCFennec Pharmaceuticals55.51%GNFTGenfit2.24%JNCEJounce Therapeutics80.66%LJPCLa Jolla Pharmaceutical97.06%Insider OwnershipCompanyInsider OwnershipBCLIBrainstorm Cell Therapeutics5.45%FENCFennec Pharmaceuticals11.25%GNFTGenfit4.20%JNCEJounce Therapeutics6.92%LJPCLa Jolla Pharmaceutical36.30%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBCLIBrainstorm Cell Therapeutics2968.34 million64.62 millionOptionableFENCFennec PharmaceuticalsN/A27.10 million24.06 millionOptionableGNFTGenfit15449.83 million47.74 millionNot OptionableJNCEJounce Therapeutics13752.63 million48.99 millionOptionableLJPCLa Jolla Pharmaceutical6124.94 million15.89 millionOptionableBCLI, JNCE, FENC, LJPC, and GNFT HeadlinesSourceHeadlineLa Jolla small business owners want lawful path to conduct business on the beachmsn.com - March 27 at 1:40 PMScripps Seaside Forumscripps.ucsd.edu - February 12 at 3:13 PMScripps Green Hospitalhealth.usnews.com - December 19 at 11:27 PM‘We may have to pull the plug’: La Jolla Christmas Parade running short of funds for Dec. 3 eventsandiegouniontribune.com - December 4 at 7:24 PM‘We lost all our fuel’: Pilot killed when small Cessna crashes in La Jollasandiegouniontribune.com - November 24 at 6:32 PMPilot killed in La Jolla neighborhood plane crash identified as Carlsbad mansandiegouniontribune.com - November 24 at 6:32 PMLa Jolla Halloween Events 2023: Trick-Or-Treats & Pumpkin Patchespatch.com - October 28 at 7:51 PMLa Jolla Pharmaceutical (NASDAQ: LJPC)fool.com - September 25 at 7:30 PMLa Jolla BJ's Hoppy Hawaiian Shirts To Benefit Maui Recovery Effortpatch.com - September 14 at 7:50 PMHepatorenal Syndrome Treatment Global Market Report 2023finance.yahoo.com - July 27 at 2:22 AMFireworks Near Me: La Jolla July 4th Events 2023patch.com - July 17 at 7:59 AMDonors Needed In La Jolla To Prevent Red Cross Blood Shortagepatch.com - July 15 at 8:21 AM2 La Jolla Students Receive 2023 National Merit Scholarshipspatch.com - July 15 at 1:10 AMJuly 4th Fireworks 2023 Near La Jollapatch.com - July 1 at 1:25 AMThalassemia Market Research | 2023-2030marketwatch.com - May 16 at 8:59 AMResults from Pivotal Phase 3 ATTACK Trial of Investigational Sulbactam-Durlobactam for Treatment of Serious Infections Caused by Acinetobacter Published in The Lancet ...businesswire.com - May 11 at 8:36 PMKidney (Renal) Fibrosis Market Report | Research Across The World 2031marketwatch.com - May 10 at 10:18 AMKidney Fibrosis Treatment Market Dynamics and Drivers: 2023-2031marketwatch.com - May 8 at 12:20 AMBased on recent market research, the Kidney/Renal Fibrosis Treatment market is set to experience robust growth, with a CAGR of 7% from 2023 to 2030.marketwatch.com - May 5 at 9:20 PMFibrodysplasia Ossificans Progressiva Drug Market Historical Trends and Future Prospect till 2031marketwatch.com - May 4 at 1:46 PMLa Jolla High Schoolusnews.com - May 3 at 10:44 PMLa Jolla aesthetician building confidence for homeless through nonprofitktvz.com - May 3 at 2:32 AMCan The Proposed Antibiotic For Multidrug-Resistant Infections Fuel Innoviva's Revenue Growth?markets.businessinsider.com - April 19 at 1:55 PMInnoviva Stock Trading Halted Todayjoplinglobe.com - April 17 at 10:08 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsBrainstorm Cell TherapeuticsNASDAQ:BCLIBrainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.Fennec PharmaceuticalsNASDAQ:FENCFennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.GenfitNASDAQ:GNFTGenfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.Jounce TherapeuticsNASDAQ:JNCEJounce Therapeutics, Inc. is a clinical stage immunotherapy company, which engages in developing treatments for cancer. It also provides novel cancer immunotherapies to attack tumors. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber, and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA.La Jolla PharmaceuticalNASDAQ:LJPCLa Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases. The company offers GIAPREZA, a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock; and XERAVA, a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. It offers GIAPREZA and XERAVA to hospitals and other healthcare organizations in the United States. Its product candidates that are in early stage clinical or preclinical development include TP-6076, an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria; TP-271, an IV and oral formulation of a fully synthetic fluorocycline for the treatment of respiratory disease caused by bacterial biothreat and antibiotic-resistant public health pathogens, as well as bacterial pathogens associated with community-acquired bacterial pneumonia; and TP-2846, an IV formulation of a tetracycline for the treatment of acute myeloid leukemia. The company has license agreement with Everest Medicines Limited to develop and commercialize XERAVA; and PAION AG to commercialize GIAPREZA and XERAVA. La Jolla Pharmaceutical Company was incorporated in 1989 and is based in Waltham, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.